RealTime Dynamix analysts believe gastroenterologists and payers may thwart the widespread adaptation of biosimilars.
Here's what you should know:
1. Approximately 103 gastroenterologists reported declining Remicade use since 2016. RTD analysts attribute this decline to gastroenterologists placing patients on Humira to avoid payer mandates related to biosimilar use.
2. Thirty-three percent of respondents indicated if a payer recommends Inflectra over Remicade, they'd likely choose an alternate TNF-inhibitor. However, only 20 percent of respondents said a payer advised them as such.
3. Gastroenterologists noted payer mandates on biosimilars were stopping mass adaptation. However, RTD analysts believe payers will be forced to cover biosimilars, once more biosimilars emerge on the market and offer cheaper alternatives to the drugs.
4. RTD analysts believe future oral treatments currently in the pipeline have the potential to allow for widespread access to the drugs.